Maglo Koffi N
Department of Philosophy, University of Cincinnati, Cincinnati, OH 45221-0374, USA.
Perspect Biol Med. 2012 Winter;55(1):137-54. doi: 10.1353/pbm.2012.0006.
This article addresses the philosophical and moral foundations of group-based and individualized therapy in connection with population care equality. The U.S. Food and Drug Administration (FDA) recently modified its public health policy by seeking to enhance the efficacy and equality of care through the approval of group-specific prescriptions and doses for some drugs. In the age of genomics, when individualization of care increasingly has become a major concern, investigating the relationship between population health, stratified medicine, and personalized therapy can improve our understanding of the ethical and biomedical implications of genomic medicine. I suggest that the need to optimize population health through population substructure-sensitive research and the need to individualize care through genetically targeted therapies are not necessarily incompatible. Accordingly, the article reconceptualizes a unified goal for modern scientific medicine in terms of individualized equal care.
本文探讨了群体治疗和个体化治疗在人口医疗平等方面的哲学和道德基础。美国食品药品监督管理局（FDA）最近修改了其公共卫生政策，试图通过批准某些药物的群体特定处方和剂量来提高治疗效果和平等性。在基因组学时代，当医疗个体化日益成为主要关注点时，研究人口健康、分层医学和个性化治疗之间的关系，有助于我们更好地理解基因组医学在伦理和生物医学方面的影响。我认为，通过对人口亚结构敏感的研究来优化人口健康的需求，与通过基因靶向治疗实现医疗个体化的需求不一定相互矛盾。因此，本文从个体化平等医疗的角度重新构想了现代科学医学的统一目标。
